Project Grant R44HL172570
Award Date
9/17/24
Completion Date
6/30/26
Dollars Obligated
$477K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $310,948 Project Grant to Minnesota Healthsolutions Corporation, a for-profit woman-owned small business, on September 15, 2023. The grant funds the development of an adaptable platform to support patients with behavior change interventions aimed at improving adherence to treatment and prevention for multiple chronic diseases. The platform will utilize remote...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $269,922 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Steth X Microsystems Inc. to develop a smart, wearable contact microphone patch for extended and remote monitoring of lung functions. The goal is to create a low-profile, battery-powered wireless device capable of accurately detecting and quantifying adventitious lung sounds as well as breathing abnormalities in patients with respiratory...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $604,750 to Scientific Horizons Consulting LLC to develop a novel inhalation device prototype for the pulmonary delivery of anti-inflammatory agents to the distal airways of patients with chronic obstructive pulmonary disease (COPD). The key products and services to be delivered include: Investigating the feasibility of aerosolizing and delivering...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $371,021 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Makani Science Inc., a minority-owned small business located in Irvine, California. The grant aims to develop an accurate and continuous monitoring platform to better characterize and classify apnea of prematurity (AOP) in premature newborns. The 24-month project will involve developing a multimodal hardware and software prototype,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $394,200 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Weill Medical College of Cornell University. The grant supports the development and pilot testing of the COPDHEART intervention, a multicomponent behavioral program tailored to improve cardiovascular health among Black adults with chronic obstructive pulmonary disease (COPD). The project aims to identify barriers, refine the intervention...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $299,995 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Nanite Inc., a small disadvantaged business in Massachusetts. The grant will fund the development of computationally-designed polymer-based delivery vehicles for mRNA payloads to treat cystic fibrosis (CF), a debilitating genetic disorder affecting the lungs. The project aims to leverage computational modeling and high-throughput polymer...
This $203,974 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a research project to investigate the effects of normal and diseased extracellular matrix (ECM) on the self-renewal and differentiation of airway basal epithelial cells. The project leverages novel tools developed by the co-PIs, including "inside-out" airway organoids and ECM hydrogels derived from normal and...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $400,000 Project Grant to Electronic Biosciences, Inc. on Sep 20, 2024. The grant supports the development of an innovative analytical testing device to quantitatively characterize lipoprotein particles in blood. This technology will enable rapid, precise, and cost-effective measurement of lipoprotein size, concentration, and other physical properties, which are...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $288,986 to Biotherapeutics, Inc., a biotechnology company in Blacksburg, VA. The grant supports the development of a novel oral immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) Determine the safety profile and pharmacokinetics of the new therapeutic in rats, and 2) Characterize the therapeutic...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $773,916 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, Ohio. The 5-year grant, which runs from August 2024 to June 2029, aims to create and validate a tool to calculate the contribution of each phenotype of bronchopulmonary dysplasia (BPD) to elevated breathing effort, known as the work of breathing (WOB), in premature neonates. The research...